EP3863615A4 - Procédés de traitement de cancers à tumeur solide à l'aide d'illudines et de biomarqueurs - Google Patents

Procédés de traitement de cancers à tumeur solide à l'aide d'illudines et de biomarqueurs Download PDF

Info

Publication number
EP3863615A4
EP3863615A4 EP19872565.7A EP19872565A EP3863615A4 EP 3863615 A4 EP3863615 A4 EP 3863615A4 EP 19872565 A EP19872565 A EP 19872565A EP 3863615 A4 EP3863615 A4 EP 3863615A4
Authority
EP
European Patent Office
Prior art keywords
illudins
biomarkers
treatment
methods
solid tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19872565.7A
Other languages
German (de)
English (en)
Other versions
EP3863615A1 (fr
Inventor
Aditya KULKAMI
Yuvanesh VEDARAJU
Umesh KATHAD
Arun ASAITHAMBI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of EP3863615A1 publication Critical patent/EP3863615A1/fr
Publication of EP3863615A4 publication Critical patent/EP3863615A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19872565.7A 2018-10-14 2019-10-14 Procédés de traitement de cancers à tumeur solide à l'aide d'illudines et de biomarqueurs Pending EP3863615A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745382P 2018-10-14 2018-10-14
PCT/US2019/056039 WO2020081414A1 (fr) 2018-10-14 2019-10-14 Procédés de traitement de cancers à tumeur solide à l'aide d'illudines et de biomarqueurs

Publications (2)

Publication Number Publication Date
EP3863615A1 EP3863615A1 (fr) 2021-08-18
EP3863615A4 true EP3863615A4 (fr) 2022-08-03

Family

ID=70284107

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19872565.7A Pending EP3863615A4 (fr) 2018-10-14 2019-10-14 Procédés de traitement de cancers à tumeur solide à l'aide d'illudines et de biomarqueurs

Country Status (6)

Country Link
EP (1) EP3863615A4 (fr)
JP (1) JP2022513349A (fr)
CN (1) CN113194934A (fr)
AU (1) AU2019361781A1 (fr)
CA (1) CA3116552A1 (fr)
WO (1) WO2020081414A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230109696A (ko) * 2020-11-18 2023-07-20 랜턴 파마 인코포레이티드 암 약물 민감도 결정 마커
EP4274662A2 (fr) * 2021-01-08 2023-11-15 Lantern Pharma Inc. Traitement de métastases cérébrales et de métastases du système nerveux central à l'aide d'illudines ou d'hydroxyluréeméthyl acylfulvène
EP4376821A1 (fr) * 2021-07-29 2024-06-05 Lantern Pharma Inc. Traitement de cancers avec des combinaisons de spironolactone et d'acylfulvènes
WO2023010119A1 (fr) * 2021-07-29 2023-02-02 Lantern Pharma Inc. Traitement de cancers avec des associations d'inhibiteur de parp et d'acylfulvènes
WO2024016014A2 (fr) * 2022-07-15 2024-01-18 Lantern Pharma Inc. Méthode de traitement de cancers du sein et de cancers du sein résistant à parp
CN116287275B (zh) * 2023-04-10 2024-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用
CN117233391A (zh) * 2023-08-28 2023-12-15 南方医科大学南方医院 一种用于预测胃癌免疫治疗和/或化疗疗效的生物标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019308A2 (fr) * 2005-08-03 2007-02-15 The Regents Of The University Of California Analogues d'illudine utiles en tant qu'agents anticancereux
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018170230A1 (fr) * 2017-03-15 2018-09-20 Memorial Sloan Kettering Cancer Center Diagnostic et traitement du cancer à mutant ercc3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10285955B2 (en) * 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
EP3129357B1 (fr) * 2014-04-10 2023-08-23 AF Chemicals LLC Conjugués de médicament et d'élément d'affinité

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019308A2 (fr) * 2005-08-03 2007-02-15 The Regents Of The University Of California Analogues d'illudine utiles en tant qu'agents anticancereux
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018170230A1 (fr) * 2017-03-15 2018-09-20 Memorial Sloan Kettering Cancer Center Diagnostic et traitement du cancer à mutant ercc3

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARINA TANASOVA ET AL: "Chemistry and Biology of Acylfulvenes: Sesquiterpene-Derived Antitumor Agents", CHEMICAL REVIEWS, vol. 112, no. 6, 6 April 2012 (2012-04-06), US, pages 3578 - 3610, XP055665990, ISSN: 0009-2665, DOI: 10.1021/cr2001367 *
See also references of WO2020081414A1 *
STAAKE MICHAEL D ET AL: "Hydroxyurea derivatives of irofulven with improved antitumor efficacy", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 7, 13 February 2016 (2016-02-13), pages 1836 - 1838, XP029453930, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.02.028 *

Also Published As

Publication number Publication date
CN113194934A (zh) 2021-07-30
AU2019361781A1 (en) 2021-06-03
JP2022513349A (ja) 2022-02-07
EP3863615A1 (fr) 2021-08-18
WO2020081414A1 (fr) 2020-04-23
CA3116552A1 (fr) 2020-04-23

Similar Documents

Publication Publication Date Title
EP3863615A4 (fr) Procédés de traitement de cancers à tumeur solide à l&#39;aide d&#39;illudines et de biomarqueurs
EP3707158A4 (fr) Biomarqueurs du cancer et leurs procédés d&#39;utilisation
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3580560A4 (fr) Méthodes pour la détection et le traitement du cancer du poumon
EP3775877A4 (fr) Biomarqueurs sériques du cancer et leurs méthodes d&#39;utilisation
EP3883580A4 (fr) Méthodes de traitement de cancers
EP3600393A4 (fr) Polythérapie pour le traitement de cancers solides et hématologiques
EP3801563A4 (fr) Matériels et procédés de traitement du cancer
EP3836909A4 (fr) Biomarqueurs pour la cancérothérapie
IL285807A (en) Immunotherapy for cancer treatment
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3775171A4 (fr) Procédés de traitement d&#39;un cancer résiduel minimal
EP3873205A4 (fr) Substances et méthodes pour le traitement du cancer
EP3870104A4 (fr) Méthodes et substances pour le traitement du cancer
EP3860610A4 (fr) Polythérapie pour le traitement du cancer
EP3673267A4 (fr) Procédés pour le diagnostic et le traitement du cancer du poumon
EP3908650A4 (fr) Méthodes de traitement du cancer
EP3820492A4 (fr) Apmv et utilisations associées pour le traitement du cancer
EP3897650A4 (fr) Polythérapie pour le traitement du cancer
EP3852816A4 (fr) Méthodes de traitement de cancer
EP3781215A4 (fr) Méthodes de traitement du cancer
EP3849544A4 (fr) Polythérapie pour le traitement du cancer de la prostate
EP3802851A4 (fr) Matériaux et procédés de traitement de troubles et de cancer liés au stress
EP3773625A4 (fr) Méthodes et matériels pour le traitement du cancer
EP3810807A4 (fr) Méthodes et compositions pour l&#39;analyse de biomarqueurs du cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060097

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220630

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6886 20180101ALI20220627BHEP

Ipc: A61P 35/00 20060101ALI20220627BHEP

Ipc: A61K 31/17 20060101ALI20220627BHEP

Ipc: C12Q 1/686 20180101ALI20220627BHEP

Ipc: C07C 239/14 20060101ALI20220627BHEP

Ipc: A61K 31/122 20060101AFI20220627BHEP